Status:
UNKNOWN
Combination of Hypofractionated Proton Therapy With Immunotherapy
Lead Sponsor:
Peking University First Hospital
Collaborating Sponsors:
YiZhou International Cancer Hospital
Conditions:
Proton Therapy
Immunotherapy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using hypofractionated proton radiation therapy in combination with immunotherapy(ie. Programme...
Detailed Description
Hypofractionated radiotherapy (HFRT), also known as Stereotactic body radiation therapy (SBRT) or Stereotactic ablative radiotherapy (SABR), is a regular pattern of photon radiotherapy. HFRT could ach...
Eligibility Criteria
Inclusion
- Pathologically confirmed Unspecified Adult Solid Tumor
- Intending to be treated with proton beam and immunotherapy
- Age ≥ 18 years old
- KPS≥70
- Signed written informed consent.
Exclusion
- Pregnant or breastfeeding woman
- Patient under guardianship or tutorship
- Patients or legal guardians who are unable to understand informed consent document
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03764787
Start Date
January 1 2019
End Date
December 1 2021
Last Update
December 5 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.